ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Environment

Pfizer, Universities Research Diabetes

May 5, 2008 | APPEARED IN VOLUME 86, ISSUE 18

Pfizer has set up a collaboration with Entelos, a Foster City, Calif.-based computer modeling company, and four major research universities: Caltech; MIT; the University of Massachusetts; and the University of California, Santa Barbara. Together they will study insulin signaling in adipose (or fat) cells with the goals of understanding diabetes and obesity and finding new drug targets. In the first phase, researchers at Pfizer, MIT, and UMass will collect and analyze data, which will then be fed to computational groups at MIT, Caltech, and UCSB. Pfizer is funding the initial three-year, $14 million insulin resistance pathway project. If it is successful, a second, two-year program will look at other insulin-sensitive tissues.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment